The UK is witnessing a growing surge in interest surrounding entheogenic substances. Beyond the common use of psilocybin and LSD, researchers and enthusiasts are increasingly focused on less-charted territories, particularly the copyright compound and the budding cannabinoid, CBG. This expanding scene encompasses clinical trials into psychological